The popular weight-loss drug Wegovy has been linked to a heightened risk of gastrointestinal issues,some of which can be severe,according to a recent update to its warning label by the U.S. Food and Drug Administration (FDA).
The FDA added this cautionary note to the label of the widely-used GLP-1 treatment at the end of November. Clinical trial participants taking Wegovy were found to be more likely to report “severe gastrointestinal adverse reactions,” the updated label states.
The FDA specifically warns that individuals with severe gastroparesis — a condition characterized by delayed stomach emptying, leading to nausea and pain — “should not take the weight loss drug,” as stated in the updated label.
While milder gastrointestinal side effects, such as nausea and constipation, are commonly associated with GLP-1 receptor agonists like Wegovy, the new warning highlights the potential for more serious complications.
“Patients should inform their doctor if they experience severe stomach problems or if their existing stomach issues persist,” the updated label advises.
Interestingly, the FDA did not issue similar updates to the warning labels of other GLP-1 drugs, including Ozempic, Rybelsus, Saxenda, Victoza, Mounjaro, and Zepbound. Notably, at least one of these medications, Zepbound, already included a warning for individuals with severe gastroparesis and severe gastrointestinal disease.
GLP-1 medications are prescribed for both weight loss and diabetes management, as well as other health conditions. A recent survey by the Kaiser Family Foundation found that approximately 12% of American adults have used a GLP-1 drug at some point.
The popular weight-loss drug Wegovy has received an updated warning from the U.S. food and Drug Administration (FDA) regarding potential complications during anesthesia. This new warning comes just weeks after another alert was issued concerning the drug’s potential to increase the risk of inhaling stomach contents into the lungs during surgical procedures.
The FDA’s updated warning for Wegovy, a GLP-1 receptor agonist, highlights the possibility of delayed stomach emptying, a known side effect of these medications. This delay can lead to food or gastric juices remaining in the stomach for extended periods, increasing the risk of aspiration during anesthesia.
“Wegovy and other GLP-1 receptor agonists have been shown to slow gastric emptying, which can increase the risk of aspiration during anesthesia,” the FDA stated in its updated warning. “Healthcare providers should be aware of this potential risk and take appropriate precautions when administering anesthesia to patients taking these medications.”
This latest warning follows a November 1st alert from the FDA concerning a potential increased risk of aspiration in patients taking GLP-1 receptor agonists,including Wegovy and Ozempic. medical professionals have long been aware of this potential risk associated with these drugs.
More serious side effects, such as gastroparesis (a condition that slows or stops the movement of food from the stomach to the small intestine), have also been linked to GLP-1 receptor agonists. A 2023 study published in the National Library of Medicine found an association between these medications and an increased risk of gastroparesis. Further studies presented in 2024 corroborated this link.
“It’s critically important for patients taking Wegovy or other GLP-1 receptor agonists to discuss their medication history with their healthcare provider before undergoing any surgical procedure requiring anesthesia,” said Dr. [Insert Name], a leading expert in [Relevant medical Field]. “This will allow the medical team to take appropriate precautions and minimize the risk of complications.”
wegovy, manufactured by Novo Nordisk, has gained important popularity as a weight-loss treatment. However, these recent FDA warnings underscore the importance of carefully considering the potential risks and benefits of any medication, especially before undergoing anesthesia.
In a shocking turn of events, Brian Thompson, the CEO of UnitedHealthcare’s insurance division, was fatally shot in New York City on Tuesday. The incident occurred as the healthcare giant was hosting an investor day in Manhattan.
“Clearly targeted,” a police source described the shooting,highlighting the deliberate nature of the attack. Details surrounding the motive and the identity of the shooter remain scarce as authorities continue their examination.
The tragic incident has sent shockwaves through the healthcare industry and beyond. Thompson was a respected leader in the field,known for his dedication to improving access to quality healthcare.
“This is a devastating loss for our company and for the healthcare community,” said a spokesperson for UnitedHealth group. “Brian was a visionary leader who made a profound impact on the lives of millions of people.”
UnitedHealth Group,the parent company of UnitedHealthcare,has pledged full cooperation with law enforcement in the ongoing investigation.The company is also providing support to Thompson’s family and colleagues during this arduous time.
texas Woman’s University (TWU) fashion students are making a difference in the lives of patients at the Scottish Rite for Children hospital. The students have designed a line of adaptive clothing aimed at enhancing comfort and confidence for children with disabilities.
“It’s about making them feel good about themselves,” said one student designer. “We want to create clothes that are both functional and fashionable.”
The project is a collaboration between TWU’s fashion design program and the Scottish Rite hospital. Students worked closely with therapists and patients to understand their needs and preferences. the resulting designs feature innovative closures, adjustable features, and sensory-friendly fabrics.
“We want these clothes to be something that kids are excited to wear,” said another student. “We want them to feel confident and comfortable in their own skin.”
The adaptive clothing line is expected to be available to Scottish Rite patients later this year.
## expert Interview: Wegovy’s Gastrointestinal Risks Under Scrutiny
**world-Today-News.com:** Thank you for joining us, Dr. [Insert Name]. Recent FDA warnings concerning Wegovy and other GLP-1 drugs are raising concerns about potential gastrointestinal risks. Could you shed some light on these concerns for our readers?
**Dr. [Insert Name]:** Certainly. Wegovy, along with other medications called GLP-1 receptor agonists, have been shown to be effective for weight loss and managing diabetes. though, they can also slow gastric emptying, wich means food stays in the stomach longer than usual.This delayed emptying can lead to a higher risk of aspiration, especially during anesthesia.
**World-Today-News.com:** Aspiration? Could you explain what that means and why it’s a concern during surgery?
**Dr. [Insert Name]:** Aspiration occurs when stomach contents, like food or acidic fluids, enter the lungs. This can be very dangerous, leading to pneumonia and other serious complications. During surgery, patients are ofen unconscious and unable to protect their airways, making aspiration more likely.
**World-Today-News.com:** Does this mean people taking Wegovy should avoid surgery altogether?
**Dr. [Insert Name]:** Not necessarily. It’s crucial for patients to inform their doctor about any medications they are taking, including Wegovy, before any surgical procedure. This allows the medical team to take appropriate precautions, such as adjusting anesthesia protocols or using a breathing tube to protect the airway.
**World-Today-News.com:** The FDA updated Wegovy’s label specifically to warn about gastrointestinal issues. What kind of gastrointestinal problems can arise from taking Wegovy?
**Dr. [Insert Name]:** While milder side effects like nausea and constipation are common with GLP-1 agonists, Wegovy has been linked to more severe gastrointestinal issues, including gastroparesis. Gastroparesis substantially slows stomach emptying and can cause persistent nausea, vomiting, and abdominal pain.
**World-Today-News.com:** Are other GLP-1 drugs also associated with these risks?
**Dr. [Insert Name]:** Yes, other GLP-1 drugs, like Ozempic and Rybelsus, also carry these risks, though they haven’t received the same recent label updates as Wegovy. It’s vital to remember that all medications have potential side effects, and individual responses can vary.
**World-Today-News.com:** What should individuals taking Wegovy or other GLP-1 drugs do to minimize their risk?
**dr. [Insert Name]:** Firstly, open communication with your doctor is crucial.
Be clear about any gastrointestinal symptoms you experience, especially severe ones.
Secondly,inform your healthcare provider about any upcoming surgical procedures.
They can take necessary steps to mitigate the risk of aspiration.
**World-Today-News.com:** Thank you,Dr. [Insert Name], for providing this valuable insight. We hope this data helps our readers make informed decisions about their health.
